Here is a compiled review of the most significant insider trading activity filed and reported through Wednesday, July 29, 2026. The disclosures span a range of sectors - banking, specialty finance, biotechnology and healthcare, asset management, and cloud/AI infrastructure - and include both purchases from company directors and officers and multi-million-dollar disposals from senior executives and large shareholders.
Top insider buys
CVB Financial Corp. (NASDAQ:CVBF)
Director Raymond V. OBrien III expanded his direct stake in CVB Financial by acquiring 20,000 shares of common stock in transactions executed on July 28, 2026. The purchases totaled approximately $455,300 and were executed at prices ranging from $22.73 to $22.86 per share, producing a weighted average purchase price of $22.765. After these purchases, Mr. OBrien directly holds 85,780 shares of CVB Financial common stock.
Those insider buys come as CVBF trades close to its 52-week high of $23.36, with the stock up roughly 25% year-to-date. InvestingPro analysis cited in the disclosures indicates the shares appear slightly overvalued relative to InvestingPro's Fair Value measure. Additional InvestingPro context referenced alongside the filing notes that six analysts have revised their earnings estimates upward for the upcoming period, and that CVB Financial has maintained dividend payments for 38 consecutive years, yielding approximately 3.51% at the time of the report.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI)
Chief Executive Officer and Chief Financial Officer Snehal Patel purchased 1,500 shares of Greenwich LifeSciences common stock on July 27, 2026, paying $13.62 per share for a total investment of $20,430. The buy is notable given the stocks recent performance: shares trade near $13.45, down about 61% from a 52-week high of $34.10 and down 55% over the prior six months.
InvestingPro analysis included with the filing characterizes GLSI as currently overvalued relative to its Fair Value. Despite that assessment, the package of analyst price targets referenced in the filing ranges from $45 to $69. The filing also documents that Mr. Patel serves as a director and is a beneficial owner of roughly 10% of the company, and that following this direct purchase he beneficially owns 5,609,202 shares of Greenwich LifeSciences common stock.
Dolphin Entertainment, Inc. (NASDAQ:DLPN)
William ODowd IV, Chief Executive Officer and a director of Dolphin Entertainment, bought 4,400 shares of the company's common stock on July 27, 2026. The transactions recorded prices ranging from $1.095 to $1.13 per share, resulting in a weighted average price of $1.11 and aggregate consideration of $4,884.
The timing of Mr. ODowd's purchase aligns with a depressed market price: Dolphins stock was trading at $1.03, only about 4% above its 52-week low of $0.99 and after a 39% decline over the prior six months. InvestingPro commentary attached to the filing indicates that DLPN appears undervalued at current market levels.
BioCardia, Inc. (NASDAQ:BCDA)
President and Chief Executive Officer Peter Altman purchased 5,000 shares of BioCardia common stock on July 29, 2026. The trades were executed at prices between $0.77 and $0.80 per share, with a weighted average price of $0.78 and a total purchase value of $3,900. The shares were acquired as BCDA was trading near its 52-week low of $0.75 and had declined approximately 14.5% over the previous week.
InvestingPro analysis noted in the filing assesses BCDA as appearing undervalued at current prices and cites a Fair Value estimate of $0.81. Following the transaction, Mr. Altman directly holds 373,885 shares of BioCardia common stock.
RENN Fund, Inc. (NASDAQ:RCG)
Horizon Kinetics Asset Management LLC, acting in its capacity as a significant shareholder and as investment adviser to RENN Fund, purchased 756 shares of RCG common stock on July 28, 2026, at a price of $3.05 per share. The transaction was valued at $2,305 and reflects the investment adviser's pecuniary interest through various managed accounts. The filing clarifies that Horizon Kinetics Asset Management LLC is a wholly owned subsidiary of Horizon Kinetics Holding Corporation and serves as the fund's investment adviser.
At the time of the filing, RENN Fund was trading at $3.03 with a market capitalization of $21.24 million and had delivered a 14.4% year-to-date return.
Top insider sells
Charles Schwab Corp. (NASDAQ:SCHW)
Co-Chairman and director Walter W. Bettinger reported sales of company shares totaling about $29.7 million across transactions carried out on July 27 and July 28, 2026, as disclosed on a recent SEC Form 4. The sold shares were held indirectly by a Family Trust.
On July 27, Mr. Bettinger sold 192,488 shares at prices ranging from $103.61 to $104.27, producing a weighted average sale price of $103.9022. On July 28, he disposed of another 93,408 shares in multiple tranches: 42,265 shares at a weighted average price of $103.86 (trades from $103.51 to $104.50); 38,263 shares at a weighted average price of $105.1848 (trades from $104.51 to $105.50); and 12,880 shares at a weighted average price of $105.5636 (trades from $105.51 to $105.625).
These sales occurred while Schwab's stock traded near a 52-week high of $107.50. InvestingPro analysis referenced in the filings indicates Schwab's shares remain on the platform's Most Undervalued list and appear undervalued at current levels. Additional metrics noted in the disclosure include a price-to-earnings ratio of 19.2, a PEG ratio of 0.4, a market capitalization of $184.3 billion, and reported revenue growth of 20% over the last twelve months.
CoreWeave, Inc. (NASDAQ:CRWV)
Chief Development Officer Brannin McBee reported the sale of 237,000 shares of CoreWeave Class A Common Stock on July 27, 2026, under a Rule 10b5-1 trading plan adopted on March 5, 2026. The sales generated proceeds of $16,836,129, with per-share prices ranging from $70.354 to $74.2996.
The report details that 144,000 of the sold shares were held directly by Mr. McBee. In addition, 25,000 shares were sold indirectly by his spouse; another 25,000 shares were sold by the Brannin J. McBee 2022 Irrevocable Trust (for which his spouse serves as trustee); 3,000 shares were sold by the Canis Major 2024 Irrevocable Trust LLC (where he serves as manager); and 40,000 shares were sold indirectly by the Canis Major 2025 Grantor Retained Annuity Trust (for which Mr. McBee is the sole trustee and beneficiary).
InvestingPro data included with the filing indicates CoreWeave shares had declined 25% over the past week and were trading near a 52-week low of $60.55, with a reported trading price of $60.82 at the time of the disclosure.
BancFirst Corp (NASDAQ:BANF)
Director and 10% owner David E. Rainbolt sold 81,492 shares of BancFirst common stock on July 28, 2026, realizing proceeds of approximately $9.5 million based on a reported per-share transaction price of $116.7113. The stock was trading at $113.83 at the time of the report, below the transaction price.
InvestingPro analysis cited in the filing indicates BANF appears undervalued relative to its Fair Value. The filing also references that the company has a record of raising its dividend for 28 consecutive years.
Ameriprise Financial Inc. (NYSE:AMP)
William Jerryl Williams, President of the Wealth Management Advisor Group at Ameriprise, sold a total of 16,104 shares of common stock across transactions on July 27 and July 28, 2026. The aggregate value of those sales was roughly $8,667,768, with execution prices spanning $537.0762 to $541.9 per share. On July 27, 7,888 shares were sold at a weighted average price of $537.0762 (individual prices between $536.48 and $537.47). Also on July 27, 6 additional shares were sold at a weighted average of $537.6067 (prices between $537.54 and $537.62). On July 28, Mr. Williams sold 4,102 shares at $538.23; 3,200 shares at a weighted average price of $540.069 (pricing between $539.57 and $540.498); and 908 shares at $541.9.
Those sales took place while Ameriprise was trading near a 52-week high of $553.46 and was quoted at $540.29 in the disclosure. InvestingPro's analysis noted in the filing characterizes Ameriprise as undervalued versus its Fair Value and lists it among the most undervalued stocks in the capital markets sector.
Intuitive Surgical Inc. (NASDAQ:ISRG)
Mark Brosius, Executive Vice President and Chief Manufacturing and Supply Chain Officer at Intuitive Surgical, sold 84 shares of the company's common stock between July 27 and July 29, 2026, for total proceeds of $29,954. The per-share sale prices ranged from $344.00 to $365.58. These transactions were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that is scheduled to expire on February 14, 2027. After these sales, Mr. Brosius retains direct ownership of 1,322 shares of Intuitive Surgical common stock.
The insider selling occurred while Intuitive Surgical trades near a 52-week low of $328.57 and was quoted at $353.10, having fallen 38% year-to-date. InvestingPro analysis included with the filing suggests ISRG appears undervalued relative to its Fair Value and places the company on the platform's Most Undervalued list. The filing also referenced that 21 analysts have revised earnings estimates upward for the upcoming period, as noted in InvestingPro Tips.
Context and considerations
Insider transactions can provide incremental data points for investors assessing executive and director sentiment toward their firm's stock price and prospects. The filings summarized here include both purchases that may signal confidence by insiders who are increasing exposure and substantial sales that reflect liquidity events or planned dispositions, including transactions conducted under pre-arranged Rule 10b5-1 plans.
It is important to note the filings themselves do not attribute a single motivation for sales or purchases. Executives and large shareholders may sell for many reasons - estate planning, diversification, or other personal liquidity needs - even when InvestingPro analysis contemporaneously suggests the shares may be undervalued or near notable price levels such as 52-week highs or lows. Similarly, purchases by insiders do not constitute a guarantee of future outperformance but do reflect a decision by those insiders to increase their direct holdings.
Each transaction included here is presented with the pricing bands, weighted average prices, and resultant ownership positions as disclosed. Where InvestingPro commentary was cited in the filings, it was included verbatim in the sense that the filings referenced valuations relative to InvestingPro Fair Value measures, analyst estimate revisions, dividend histories, and other metrics that contextualize the trades.
Key takeaways
- Insider buying activity on July 27-29, 2026 was led in dollar terms by a CVB Financial director's purchase of 20,000 shares, with additional purchases by executives at Greenwich LifeSciences, Dolphin Entertainment, BioCardia, and a strategic purchase by Horizon Kinetics at RENN Fund.
- Large sales were concentrated among established financial and technology names - notably Charles Schwab, CoreWeave, BancFirst, Ameriprise, and Intuitive Surgical - with several multi-million-dollar disposals and structured sales executed under Rule 10b5-1 plans.
- InvestingPro assessments accompanying the filings highlighted a mix of perceived undervaluation (for SCHW, DLPN, BCDA, BANF, AMP, ISRG, and others) and overvaluation (GLSI), while noting analyst estimate revisions and dividend histories as additional context.
Risks and uncertainties highlighted by the disclosures
- Timing risk associated with trades near notable price points - Several transactions occurred close to 52-week highs (for example, CVBF and SCHW) or lows (for example, DLPN, BCDA, and ISRG). That proximity to extreme price levels introduces uncertain short-term market dynamics for the impacted securities, particularly in the banking, biotech, and technology sectors.
- Interpretation risk of insider sales - Large sales by senior executives or major shareholders do not inherently signal negative firm prospects; they may reflect personal financial planning or structured selling through Rule 10b5-1 plans, complicating interpretation for investors evaluating management sentiment in capital markets and tech infrastructure firms.
- Valuation disagreement risk - The InvestingPro commentary accompanying the filings shows discrepancies between market prices and Fair Value estimates (for instance, GLSI assessed as overvalued while others are seen as undervalued). These valuation mismatches create uncertainty for investors in financials, biotech, and tech names as consensus views on fair price vary.
Closing
The filings reviewed for July 27-29, 2026 illustrate a mix of confidence-inspiring purchases and large-scale sales across several market segments. For investors and analysts focused on underwriting quality, funding mix, regulatory constraints, and shareholder returns - particularly in the financial sector - these disclosures provide concrete position changes and pricing details that can inform further due diligence. Tracking both the raw transaction data and the contextual InvestingPro commentary may help market participants prioritize follow-up research but does not substitute for a comprehensive, fundamental assessment of each company.